Olanzapine-induced destabilization of diabetes in the absence of weight gain.
OBJECTIVE
To provide evidence that olanzapine can cause glucose dysregulation by a mechanism other than weight gain.


METHODS
I report a case of a diabetic patient who developed glucose dysregulation soon after initiation of olanzapine treatment, occurring in the absence of weight gain. I compare this case to previous case reports.


RESULTS
Our patient developed persistent hyperglycaemia within 3 weeks of initiating treatment with olanzapine. Weight recorded just prior to commencement and soon after discontinuation of olanzapine were not significantly different.


CONCLUSIONS
Controlled studies are necessary to elucidate the mechanism by which olanzapine can cause dysregulation of glucose homeostasis, and to develop guidelines for the use of olanzapine in patients with known diabetes as well as in patients with risk factors for diabetes.
Ramankutty
G
G
Auckland Regional Psychiatric Registrar Training Centre, Auckland, New Zealand. ramankutty@orxon.net.nz
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000378:metabolism; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001786:Blood Glucose; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine